Cromos Pharma
Cromos Pharma is an international research organization (CRO) specializing in clinical trials. Find out more by visiting www.cromospharma.com.
Established in 2004, Cromos Pharma provides tailored and effective clinical trial services to support the development of drugs that transform healthcare. It is an international CRO with over 15 years' experience in offering fully integrated services and delivering all aspects of clinical trials in all clinical phases and a range of therapeutic areas. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has strong regional experience in Central and Eastern Europe. Its US base is in Portland, Oregon with additional operations in South Florida and its European HQ is situated in Dublin, Ireland.
09/24/2026
China’s AI-TEC eye clinic offers an early look at what happens when AI moves from controlled testing into real clinical practice.
Its implementation revealed a key lesson: strong AI performance alone is not enough. Data quality, physician adoption and workflow integration can determine whether AI delivers real clinical value.
Read more: https://cromospharma.com/china-built-an-ai-agent-eye-clinic-here-is-what-happened-in-the-real-world/
We are pleased to share that Vlad Bogin, MD, FACP, CEO of Cromos Pharma, will be attending ESMO Congress 2026, taking place from October 23 to 27 in Madrid, Spain.
As one of the world’s leading oncology events, ESMO brings together the global oncology community to share the latest advances in cancer research, treatment, and clinical development. Vlad looks forward to connecting with industry leaders and discussing how Cromos Pharma’s oncology expertise and tailored clinical trial solutions can support sponsors in advancing their development programs.
To connect with Vlad during ESMO 2026 or to learn more about how Cromos Pharma can support your oncology clinical development needs, contact us at [email protected].
Best,
09/22/2026
Alzheimer’s clinical research is entering a new era.
Earlier intervention, blood biomarkers, new therapeutic targets and increasingly complex trial designs are changing how Alzheimer’s studies are planned and conducted.
On World Alzheimer’s Day, we look at five key developments reshaping Alzheimer’s clinical trials and what they mean for sponsors.
Read more: https://cromospharma.com/world-alzheimer-s-day-2026-is-clinical-research-ready-for-the-next-era-of-alzheimer-s-trials/
Cromos Pharma is currently seeking a Senior Clinical Research Associate (CRA) to join our team.
Location: France
For additional details about this opportunity, please visit our website: https://cromospharma.com/senior-clinical-research-associate-france/
If you're ready to apply, please send your CV to [email protected]
09/16/2026
Rare disease recruitment is becoming increasingly challenging. Could sponsors be overlooking Türkiye?
Our Senior CRA I in Türkiye, Pelin Ozdemir, explores why the country deserves earlier consideration in rare disease clinical development, from patient populations and screening programs to specialist referral networks and real-world recruitment performance.
Read the full article: https://cromospharma.com/rare-disease-recruitment-is-getting-harder-is-turkiye-being-overlooked/
Cromos Pharma is currently seeking an In-house CRA to join our team.
Location: Europe
For additional details about this opportunity, please visit our website: https://cromospharma.com/in-house-cra/
If you're ready to apply, please send your CV to [email protected]
09/08/2026
The FDA rejected Replimune’s melanoma therapy twice. Then, in August 2026, it approved it.
How did a program facing fundamental questions about its clinical evidence ultimately secure accelerated approval?
We break down what changed and what this unusual regulatory reversal means for drug developers.
Read the full story: https://cromospharma.com/?p=13237&preview=true
Happy Labor Day 2026!
As Labor Day approaches, we celebrate the hard work, dedication, and commitment of people across every field whose contributions help move our communities and industries forward.
From all of us at Cromos Pharma, we wish you a relaxing Labor Day and a well-deserved break with family and friends.
09/04/2026
In the latest edition of Cromos Pharma’s Newsletter, we highlight key developments shaping clinical research and healthcare innovation:
-The FDA approves the first-ever gene therapy for glycogen storage disease type Ia.
-Merck and Moderna report positive Phase 3 results for their personalized mRNA cancer therapy.
-The FDA places a clinical hold on REGENXBIO’s RGX-121 gene therapy trial for Hunter syndrome.
Read the full Newsletter: https://cromospharma.com/clinical-research-focus-56th-edition/
08/27/2026
Clinical trial regulation is moving fast in 2026.
From Bayesian trial designs and broader oncology eligibility criteria to real-time data sharing, streamlined biosimilar development, and new GCP expectations, regulators are introducing changes that could have a direct impact on sponsors.
In our latest Cromos Pharma Regulatory Radar, we highlight 7 key FDA and European regulatory developments and what they mean for clinical development teams.
Read more: https://cromospharma.com/cromos-pharma-regulatory-radar-2026-mid-year-update/?preview_id=13183&preview_nonce=3d93bb905b&_thumbnail_id=13195&preview=true
Click here to claim your Sponsored Listing.
Telephone
Website
Address
US Bancorp Tower, 111 S. W. Fifth Avenue, Suite 3150
Portland, OR
97204